Patent spotlight: zip11 gene and the future of anti-aging therapies

Wouldn’t you want to know which vitamins and diets may extend your biological age and which may do the opposite. A recently published patent suggests how to do exactly that. And it is a major step in potentially guiding us to longevity.  Read Hot Science below.‍

Personalized medicine is all the rage now, with both patients and investors. It was proven by a whopping $400 million investment  into a new company, Mirador Therapeutics, with an objective to develop personalized treatments. Read Hot Investments below.

‍

Hot Science

In this edition, we direct attention to a significant patent that introduces a novel method related to age-related therapies, centering on the expression level of gene Zip11. The research presents notable findings: male mice with up- or down- regulated Zip11 expression exhibit  corresponding indicators of aging processes. Furthermore, the experiments showed that some substances and vitamins increase the expression of Zip11, indicating a dietary influence on mice aging. Importantly, Zip11-deficient mice demonstrate compromised immune function in macrophages, and there is an observed increase in the p53 protein level, a well-known marker of cellular aging.

Many companies, including Immorta Bio, have been using different biomarkers of aging and longevity. Adding Zip11, what appears to be another powerful Indicator in that class, is a major   contributor to the fight on the path to longevity. These insights pave the way for crafting targeted interventions in Immorta’s Treating Diseases of Aging and Treating Aging as Disease™.

‍
Hot Investments

Mirador Therapeutics was launched after securing a $400 million investment to develop personalized treatments for immune-mediated inflammatory and fibrotic diseases. Treatment of these conditions could provide a major contribution to healthy longevity. Mirador plans to use genetic profiling and advanced data analysis to tailor treatments to individual patients. By focusing on precision medicine, Mirador seeks to enhance treatment efficacy, propelling the advancement of personalized therapies for these debilitating conditions.

Personalized medicine is also Immorta Bio’s foundation in Treating Diseases of Aging and Treating Aging as Disease™. Both therapeutics directions Immorta is pursuing, Cellular Rejuvenation and Senotherapeutics are tailored to specific patients, as the interventions are  developed from the patient’s own cells with its unique DNA.

‍

Longevity Shorts

• A recent study by agelessRx confirmed that Low Dose Naltrexone (LDN), effectively reduces chronic inflammation, autoimmunity, obesity, fatigue, and chronic pain.

• Century Summit at Stanford was focused on longevity and community, among other topics.  https://www.longevity-project.com/century-summit-2023-landing-page.
• Immorta Bio's groundbreaking patents, including one for personalized regenerative cells, promise new strides in longevity patent application № 63/591063

‍

Term of the Day

What is Aging?​

As it was defined in Nature, aging is a gradual and irreversible pathophysiological process characterized by declines in tissue and cell functions and significant increases in the risks of various aging-related diseases. The longevity industry and academia, including Immorta Bio, is working hard to make this process to be reversable.

‍

Boris Reznik, PhD
Chairman